Table 4.
Association between PI3K/mTOR immunoexpression and clinicopathological parameters of TNBC.
| Parameters | PI3K Expression | mTOR Expression | ||||
|---|---|---|---|---|---|---|
| np (%) | np (%) | |||||
| Low | High | p Value | Low | High | p Value | |
| Patients | 42 (60) | 28 (40) | 39 (56) | 31 (44) | ||
| Age at diagnosis | ||||||
| <50 | 12 (29) | 7 (25) | 0.79 | 10 (26) | 9 (29) | 0.79 |
| ≥50 | 30 (71) | 21 (75) | 29 (74) | 22 (71) | ||
| Tumor type | ||||||
| Ductal | 27 (64) | 14 (50) | 0.48 | 24 (62) | 17 (55) | 0.54 |
| Lobular | 7 (17) | 6 (21) | 8 (20) | 5 (16) | ||
| Other * | 8 (19) | 8 (29) | 7 (18) | 9 (29) | ||
| Invasion # | ||||||
| Absent | 33 (80) | 21 (78) | >0.99 | 31 (82) | 23 (77) | 0.76 |
| Present | 8 (20) | 6 (22) | 7 (18) | 7 (23) | ||
| pp stage | ||||||
| I | 10 (24) | 0 (0) | 0.02 | 9 (23) | 1 (3) | 0.02 |
| II | 20 (48) | 17 (61) | 21 (54) | 16 (52) | ||
| III and IV | 12 (28) | 11 (39) | 9 (23) | 14 (45) | ||
| pT stage | ||||||
| T1 | 14 (33) | 4 (14) | 0.05 | 13 (33) | 5 (16) | 0.14 |
| T2 | 21 (50) | 22 (79) | 23 (59) | 20 (65) | ||
| T3 and T4 | 7 (17) | 2 (7) | 3 (8) | 6 (19) | ||
| pN stage | ||||||
| N0 | 26 (62) | 10 (36) | 0.04 | 24 (62) | 12 (39) | 0.15 |
| N1 | 6 (14) | 11 (39) | 7 (18) | 10 (32) | ||
| N2 and N3 | 10 (24) | 7 (25) | 8 (20) | 9 (29) | ||
| Histologic grade | ||||||
| I and II | 30 (71) | 15 (54) | 0.14 | 27 (69) | 18 (58) | 0.45 |
| III | 12 (29) | 13 (46) | 12 (31) | 13 (42) | ||
| Metastases | ||||||
| M0 | 36 (86) | 19 (68) | 0.13 | 33 (85) | 22 (71) | 0.24 |
| M1 | 6 (14) | 9 (32) | 6 (15) | 9 (29) | ||
Abbreviations: np, number of patients per group; *—medullary, tubular and other rare carcinoma types, #—data not available for two patients. Bold indicates statistically significant values, p ≤ 0.05.